<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187497</url>
  </required_header>
  <id_info>
    <org_study_id>502.268</org_study_id>
    <nct_id>NCT02187497</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of BIBR 277 in Hypertensive Patients</brief_title>
  <official_title>BIBR 277 Capsules Pharmacokinetics Study of Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The pharmacokinetic profile of BIBR 277 single dose given in capsule form to hypertensives
      was evaluated. The results of the present study are to be used in the Japanese population
      pharmacokinetics analysis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <primary_completion_date type="Actual">September 1998</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of BIBR 277 in plasma from 0 to 24 hours (AUC0-24hr)</measure>
    <time_frame>Pre-dose up to 24 hours after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time of BIBR 277 in the body from 0 to 24 hours (MRT0-24hr)</measure>
    <time_frame>Pre-dose up to 24 hours after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of BIBR 277 in plasma (Cmax)</measure>
    <time_frame>Pre-dose up to 24 hours after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from dosing to the maximum concentration of BIBR 277 in plasma (tmax)</measure>
    <time_frame>Pre-dose up to 24 hours after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-time of BIBR 277 in plasma (t1/2)</measure>
    <time_frame>Pre-dose up to 24 hours after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood pressure (systolic, diastolic, and mean)</measure>
    <time_frame>Pre-dose up to 14 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in pulse rate</measure>
    <time_frame>Pre-dose up to 14 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in laboratory test values</measure>
    <time_frame>Pre-dose up to 14 days after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Low dose of BIBR 277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose of BIBR 277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of BIBR 277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose of BIBR 277</intervention_name>
    <arm_group_label>Low dose of BIBR 277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medium dose of BIBR 277</intervention_name>
    <arm_group_label>Medium dose of BIBR 277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose of BIBR 277</intervention_name>
    <arm_group_label>High dose of BIBR 277</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt;=20 years

          -  Sex: Either male or female

          -  Patient status: Either inpatient or outpatient, provided that the patient was
             available for hospitalisation from the day before the trial medication administration
             until the morning of the day after administration

          -  BP: Sitting systolic and diastolic blood pressures (SBP and DBP) taken the day before
             administration should be &gt;= 150 mmHg and &gt;= 90 mmHg, respectively. Patients undergoing
             treatment with other antihypertensives were not excluded provided the above criteria
             were satisfied.

        Exclusion Criteria:

          -  Malignant hypertension

          -  Renovascular hypertension

          -  Severe heart failure (NYHA functional class III - IV), unstable angina pectoris, or
             history of myocardial infarction (within 6 months of onset)

          -  Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or
             serious arrhythmia

          -  Symptoms of cerebrovascular disorder

          -  Serious hepatic dysfunction

          -  Renal function disorder (serum creatinine &gt;= 4.0 mg/dL)

          -  Known hypersensitivity to angiotensin II receptor antagonists

          -  Hyperkalaemia (potassium &gt;= 5.5 milliequivalents per liter (mEq/L))

          -  Treatment with the other investigational drug within 6 months of initiation of the
             present study

          -  Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this
             study

          -  Previous treatment with the trial medication of the present study

          -  Otherwise judged ineligible by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

